A Retrospective, Nonrandomized, Multicentric Study to Evaluate the Long-Term Outcomes of Ranibizumab Monotherapy in Patients with Myopic Choroidal Neovascularization (mCNV)
Latest Information Update: 18 May 2018
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Adverse reactions; Therapeutic Use
- 18 May 2018 New trial record